Ritedose Corp. to Invest $17 Million in Laboratory Expansion

The Ritedose Corporation, a pharmaceutical manufacturer based in South Carolina, announced a $17 million investment to expand its in-house cGMP laboratory facilities, enhancing its analytical chemistry and microbiology capabilities.

The expansion, set to be completed by spring 2026, will add 10,000 square feet of laboratory space, tripling the company’s current lab footprint and enabling it to support a production capacity of 2.6 billion doses annually.

The project includes two phases. Phase I involves constructing a 10,000-square-foot analytical chemistry laboratory within Ritedose’s newly opened distribution and logistics facility at Ritedose Performance Park. This facility will separate wet lab operations from office spaces, improving workflow efficiency. Phase II will convert the existing analytical chemistry lab in Ritedose’s main building into a 6,000-square-foot microbiology lab expansion.

“By expanding our cGMP laboratory space, we’re not just meeting our current needs, we’re preparing Ritedose for the future of pharmaceutical development,” said Ritedose CEO Jody Chastain. “These investments give us the capacity, flexibility and advanced capabilities to support next-generation therapies, strengthen our regulatory leadership, and ensure we can deliver life-changing treatments to patients with even greater speed and reliability.”

The upgraded facilities will allow Ritedose to manage all laboratory functions in-house, offering turnkey solutions for customers and positioning the company as a key provider of analytical services in the life sciences sector. The labs will support a wide range of testing, including raw material qualification, finished product release, extractables and leachables, nitrosamine detection, elemental analysis, and drug product de-formulation. The expansion will also enhance Ritedose’s expertise in method development, validation, stability studies, and regulatory compliance, supporting complex chemistry, manufacturing, and controls (CMC) programs, bioequivalence studies, and regulatory submissions in line with FDA and ICH guidelines.

The investment underscores Ritedose’s strategy to bolster its role in pharmaceutical development, building on its reputation for cGMP analytical services and supporting the growing demand for advanced therapies.